Cite
HARVARD Citation
Heinrich, M. et al. (n.d.). Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST). European journal of cancer. pp. S4-. [Online].